Article
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.
Breast cancer research and treatment - 1 Jun 2010
Brown Lindsay A, Johnson Karynn, Leung Samuel, Bismar Tarek A, Benítez Javier, Foulkes William D, Huntsman David G
Abstract excerpt
Amplification of chromosome 11q13 is commonly seen in breast carcinomas and candidate genes from this region include CCND1 and EMSY. Here, we investigate the prognostic significance of CCND1 and EMSY amplification in a large series of breast carcinomas and in BRCA1 and BRCA2 mutation positive breast cancers. Amplification of CCND1 and EMSY was assessed by fluorescent in situ hybridization. Both CCND1 and EMSY...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.